otisur vet 23.0 mg/ml + 5.0 mg/ml + 5500 iu/ml korvatipat, suspensio
chanelle pharmaceuticals manufacturing limited - miconazole nitrate, polymyxin b sulfate, prednisolone acetate - korvatipat, suspensio - 23.0 mg/ml + 5.0 mg/ml + 5500 iu/ml - prednisoloni ja mikrobilääkkeet
isopto-cetapred silmätipat
s.a. alcon couvreur n.v. - sulfacetamidum natricum,prednisoloni acetas - silmätipat - prednisoloni ja mikrobilääkkeet
scheriproct rektaalivoide
schering oy - cinchocaini hydrochloridum,clemizoli undecylenas,prednisoloni caproas - rektaalivoide - prednisoloni
scheriproct peräpuikko
schering oy - cinchocaini hydrochloridum,clemizoli undecylenas,prednisoloni caproas - peräpuikko - prednisoloni
vecortenol-viof vet liuos iholle ja korviin
novartis pharma stein ag - clioquinolum,prednisoloni pivalas - liuos iholle ja korviin - prednisoloni ja mikrobilääkkeet
varecort peräpuikko
novartis consumer health sa - hexachlorophenum,troxerutinum,prednisoloni pivalas - peräpuikko - prednisoloni
blephamide silmätipat
allergan inc. - phenylephrini hydrochloridum,prednisoloni acetas,sulfacetamidum natricum - silmätipat - prednisoloni
abiraterone accord
accord healthcare s.l.u. - abirateroniasetaatti - prostatiset kasvaimet - endokriinihoito - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.
zytiga
janssen-cilag international n.v. - abirateroniasetaatti - prostatiset kasvaimet - endokriinihoito - zytiga on merkitty prednisoni tai prednisoloni:metastasoituneen kastraation kastraatioresistentin eturauhassyövän aikuiset miehet, jotka ovat oireettomia tai lievästi oireileva jälkeen epäonnistuminen androgeenideprivaatiohoito joille kemoterapiaa ei ole vielä kliinisesti indicatedthe metastasoituneen kastraation kestävä eturauhassyövän hoitoon aikuisilla miehillä, joiden tauti on edennyt, tai kun docetaxel perustuu solunsalpaajahoito.
abiraterone mylan
mylan ireland limited - abirateroniasetaatti - prostatiset kasvaimet - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.